Thomas Cooper

Abnormalities in the muscle enzyme pyruvate kinase contribute to type 1 myotonic dystrophy, an MDA-funded study has found

posted on August 19, 2013 - 3:29pm
An abnormality in a muscle enzyme known as pyruvate kinase (PKM) has been added to the list of things that go wrong in type 1 myotonic muscular dystrophy (MMD1, or DM1), a new study has found. MDA supported Thomas Cooper at Baylor College of Medicine in Houston on this study, which was published online in Proceedings of the National Academy of Sciences July 30, 2013.
posted on July 1, 2012 - 3:00pm
QUEST Vol. 19, No. 3
The complex and multifaceted disease known as myotonic muscular dystrophy (MMD) — also known as dystrophia myotonia (DM) — was the subject of an In Focus report in the April-June 2012 Quest. Here, we delve into experimental strategies that may markedly improve the outlook for people with this disorder.
posted on July 1, 2012 - 3:00pm
QUEST Vol. 19, No. 3
Thomas Cooper, a professor in the Department of Pathology and Immunology at Baylor College of Medicine, is a longtime MDA research grantee who has current MDA support to develop oligonucleotide-based therapies for myotonic muscular dystrophy (MMD, also known as DM). Margaret Wahl, MDA's medical and science editor, talked with Cooper about his research.

Researchers have used a 'gapmer antisense' strategy to destroy the genetic defect that causes type 1 myotonic dystrophy in cultured cells and in MMD1 mice

posted on February 29, 2012 - 9:58am
Researchers at Baylor College of Medicine in Houston and Isis Pharmaceuticals in Carlsbad, Calif., have announced encouraging results for their antisense-based strategy in development for the treatment of type 1 myotonic muscular dystrophy (DM1, or MMD1).